<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00766324</url>
  </required_header>
  <id_info>
    <org_study_id>AURA-6202-007</org_study_id>
    <nct_id>NCT00766324</nct_id>
  </id_info>
  <brief_title>PHA-739358 for Treatment of Hormone Refractory Prostate Cancer</brief_title>
  <official_title>A Phase II Study of PHA-739358 in Patients With Metastatic Hormone Refractory Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nerviano Medical Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nerviano Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the antitumor activity of PHA-739358 administered as IV infusion according to two
      different dose schedules in metastatic HRPC patients progressing on standard, docetaxel-based
      1st-line chemotherapy for HRPC based on PSA response, and to select the best dose schedule
      for further investigation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PSA response rate defined according to the recommendations from the Prostate-Specific Antigen Working Group</measure>
    <time_frame>within the first three months of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate, Progression Free Survival, additional PSA based endpoints, clinical benefit</measure>
    <time_frame>all cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall safety profile</measure>
    <time_frame>all cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Metastatic Hormone Refractory Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PHA-739358</intervention_name>
    <description>6-hr IV infusion weekly for 3 consecutive weeks in a 4-week cycle</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PHA-739358</intervention_name>
    <description>24-hr IV infusion every 2 weeks in a 4-week cycle</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic hormone refractory prostate cancer progressing after docetaxel based
             therapy

          -  Adequate bone marrow, liver and kidney function

        Exclusion Criteria:

          -  More than one prior chemotherapy line

          -  Uncontrolled hypertension

          -  Brain or leptomeningeal disease

          -  Myocardial infarction, severe/unstable angina, symptomatic congestive heart failure,
             cerebrovascular accident in the previous 6 months
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nerviano Medical Sciences. Clinical Research Dept.</name>
      <address>
        <city>Nerviano</city>
        <state>Milano</state>
        <zip>20014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2008</study_first_submitted>
  <study_first_submitted_qc>October 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2008</study_first_posted>
  <disposition_first_submitted>May 13, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>May 13, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 28, 2014</disposition_first_posted>
  <last_update_submitted>May 13, 2014</last_update_submitted>
  <last_update_submitted_qc>May 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

